Insider · CIK 0001653082
Jeffrey S. Heier
Files at OCUL (OCULAR THERAPEUTIX, INC). First filing Nov 27, 2024, latest Oct 6, 2026.
In brief
Jeffrey S. Heier files SEC Form 4 as officer at OCUL (OCULAR THERAPEUTIX, INC). Since Nov 27, 2024, Jeffrey S. Heier has reported 0 open-market buys worth $0 and 10 open-market sells worth $426k, the latest filed on Oct 6, 2026.
A track record needs three past buys with six months of prices behind them; Jeffrey S. Heier has 0, so none is measured yet.
The newest scored trade: sold $77k of OCUL on Oct 2, 2026, filed Oct 6, 2026, scored 11 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 5 sells worth $204k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
OCUL: OCULAR THERAPEUTIX, INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 11Weak | OCULAR THERAPEUTIX, INC | $77k 10,869 shares | -3% | +1% from low-57% from high | |
| 16Weak | OCULAR THERAPEUTIX, INC | $36k 3,296 shares | -1% | +57% from low-33% from high | |
| 10Weak | OCULAR THERAPEUTIX, INC | $25k 3,018 shares | -1% | +20% from low-49% from high | |
| 15Weak | OCULAR THERAPEUTIX, INC | $25k 3,057 shares | -1% | +42% from low-48% from high | |
| 16Weak | OCULAR THERAPEUTIX, INC | $42k 3,469 shares | -1% | +104% from low-11% from high | |
| 20Weak | OCULAR THERAPEUTIX, INC | $116k 10,502 shares | -4% | +87% from low-19% from high | |
| 16Weak | OCULAR THERAPEUTIX, INC | $37k 3,063 shares | -1% | +100% from low-6% from high | |
| 10Weak | OCULAR THERAPEUTIX, INC | $22k 3,024 shares | -1% | +23% from low-36% from high | |
| 10Weak | OCULAR THERAPEUTIX, INC | $21k 3,061 shares | -1% | - | |
| 15Weak | OCULAR THERAPEUTIX, INC | $27k 2,948 shares | -1% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 2, 2026 | OCUL OCULAR THERAPEUTIX, INC. | 10,869 0.00% of outstanding | $77k | Oct 2, 2026 | $36k |
| Aug 24, 2026 | OCUL OCULAR THERAPEUTIX, INC. | 3,296 0.00% of outstanding | $36k | Aug 24, 2026 | $25k |
| May 26, 2026 | OCUL OCULAR THERAPEUTIX, INC. | 3,018 0.00% of outstanding | $25k | May 26, 2026 | none |
| Feb 23, 2026 | OCUL OCULAR THERAPEUTIX, INC. | 3,057 0.00% of outstanding | $25k | Feb 23, 2026 | $42k |
| Nov 24, 2025 | OCUL OCULAR THERAPEUTIX, INC. | 3,469 0.00% of outstanding | $42k | Nov 24, 2025 | $153k |
| Oct 2, 2025 | OCUL OCULAR THERAPEUTIX, INC. | 10,502 0.01% of outstanding | $116k | Oct 2, 2025 | $37k |
| Aug 25, 2025 | OCUL OCULAR THERAPEUTIX, INC. | 3,063 0.00% of outstanding | $37k | Aug 25, 2025 | none |
| May 23, 2025 | OCUL OCULAR THERAPEUTIX, INC. | 3,024 0.00% of outstanding | $22k | May 23, 2025 | $21k |
| Feb 24, 2025 | OCUL OCULAR THERAPEUTIX, INC. | 3,061 0.00% of outstanding | $21k | Feb 24, 2025 | $27k |
| Nov 25, 2024 | OCUL OCULAR THERAPEUTIX, INC. | 2,948 0.00% of outstanding | $27k | Nov 25, 2024 | none |
Transactions
Every row this insider has filed, 12 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | OCUL OCULAR THERAPEUTIX, INC | SOpen-market sale Common Stock10b5-1 | -10,869 | $7.05 | $77k | 307,457 | 7 d ago |
| Aug 24, 2026 | OCUL OCULAR THERAPEUTIX, INC | SOpen-market sale Common Stock10b5-1 | -3,296 | $10.78 | $36k | 318,326 | Aug 26, 2026 |
| May 26, 2026 | OCUL OCULAR THERAPEUTIX, INC | SOpen-market sale Common Stock10b5-1 | -3,018 | $8.20 | $25k | 320,350 | May 28, 2026 |
| Feb 23, 2026 | OCUL OCULAR THERAPEUTIX, INC | SOpen-market sale Common Stock10b5-1 | -3,057 | $8.28 | $25k | 323,368 | Feb 25, 2026 |
| Jan 2, 2026 | OCUL OCULAR THERAPEUTIX, INC | AGrant or award Common Stock | +79,112 | $0.00 | $0 | 326,425 | Jan 6, 2026 |
| Jan 2, 2026 | OCUL OCULAR THERAPEUTIX, INC | AGrant or award Stock Option (Right to Buy)derivative | +240,932 | $0.00 | $0 | 240,932 | Jan 6, 2026 |
| Nov 24, 2025 | OCUL OCULAR THERAPEUTIX, INC | SOpen-market sale Common Stock10b5-1 | -3,469 | $12.04 | $42k | 245,940 | Nov 26, 2025 |
| Oct 2, 2025 | OCUL OCULAR THERAPEUTIX, INC | SOpen-market sale Common Stock10b5-1 | -10,502 | $11.04 | $116k | 249,409 | Oct 6, 2025 |
| Aug 25, 2025 | OCUL OCULAR THERAPEUTIX, INC | SOpen-market sale Common Stock10b5-1 | -3,063 | $12.04 | $37k | 259,911 | Aug 27, 2025 |
| May 23, 2025 | OCUL OCULAR THERAPEUTIX, INC | SOpen-market sale Common Stock10b5-1 | -3,024 | $7.18 | $22k | 262,974 | May 27, 2025 |
| Feb 24, 2025 | OCUL OCULAR THERAPEUTIX, INC | SOpen-market sale Common Stock10b5-1 | -3,061 | $6.87 | $21k | 265,998 | Feb 26, 2025 |
| Nov 25, 2024 | OCUL OCULAR THERAPEUTIX, INC | SOpen-market sale Common Stock10b5-1 | -2,948 | $9.01 | $27k | 269,059 | Nov 27, 2024 |
Questions about Jeffrey S. Heier
Answered from the filings on this page, as of the latest one.
Is Jeffrey S. Heier buying or selling?
In the last 12 months Jeffrey S. Heier reported 0 open-market buys worth $0 and 5 open-market sells worth $204k on SEC Form 4; the latest was sold $77k of OCUL on Oct 2, 2026. Grants, option exercises and tax withholding are not counted.
How did Jeffrey S. Heier's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jeffrey S. Heier has 0.
Where does Jeffrey S. Heier file Form 4?
Jeffrey S. Heier has filed Form 4 at OCUL (OCULAR THERAPEUTIX, INC) as Chief Scientific Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.